Contact Us

2020 West Harrison Street
Chicago, IL 60612

Phone: (312) 572-4500


The CORE Center is committed to providing leadership in infectious disease research to help patients live longer, more comfortably and more independently. The performance of high quality research is central to the CORE Center’s mission, and the Research Department has broad experience with HIV research. Clinical research, behavioral science research and natural history studies are available to our patients, including pregnant women, children and adolescents. We conduct innovative and scientific studies that are patient-sensitive, using established methods and ethical principles. Research is designed and conducted to find better treatments for our patients, to improve our understanding of infectious diseases and may involve new medications, vaccines, interviews and therapies. All studies are voluntary and available at no cost.

National Cancer Institute (NCI) Funded

AIDS Malignancy Clinical Trials Consortium (AMC)

The AMC is a clinical trials group that supports innovative trials for AIDS-related cancers. AMC working groups deal with the cancers that affect HIV-positive patients including Kaposi’s sarcoma, Lymphoma, Human Papillomavirus-related Cancers and Non-AIDS Defining Cancers (such as lung and liver cancer). In 2011 Stroger Hospital/CORE Center joined the AMC as an affiliate clinical trials site. For more information, visit the AMC website at

National Institutes of Health (NIH) Funded

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study Scale-Up (CHOICES)

This NIDA funded research compares the effect of medical office-based extended-release naltrexone vs treatment as usual for HIV-infected participants with untreated opioid use disorder who are at risk of HIV viral non-suppression, or lacking suppression at baseline. For additional information, contact the Project Coordinator at (312) 572-4573

International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT)

The IMPAACT mission is to evaluate treatment for perinatally HIV-infected children and adolescents and pregnant women, including prevention of co-infections and co-morbidities. This study group conducts trials of novel pharmaceutical and immune therapies, vaccines and strategies for best use of existing antiretroviral medications in perinatally infected children. For additional information, contact the Project Coordinator at (312) 572-4541

Keeping it LITE: Limited Interaction Targeted Epidemiology

Funded by NIAID/NIMH, this longitudinal study will help us learn more about HIV prevention and transmission in young people. Featuring “at-home HIV testing and surveys”, the study will recruit, enroll and retain participants through the use of social media and electronic advertisement. Enrollment is targeting HIV uninfected MSM and TGW, ages 13-34 years, at high risk of HIV acquisition.

Multicenter AIDS Cohort Study (MACS)

The first longitudinal HIV research federally funded, MACS is a prospective study of the natural and treated histories of HIV-1 infection in men conducted by sites located in Baltimore, Chicago, Pittsburgh and Los Angeles. The CORE Center cohort augments research efforts in the long-term benefits and adverse effects of therapy on men of color—over 150 men have participated at CORE since enrollment began in 2002. For additional information, visit the national website at

STAR Sexually Transmitted Infection Clinical Trials Group: Placebo Controlled Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis

This NIAID-funded research will assess the efficacy of repeated doses of a new treatment, LACTIN-V, compared to placebo in preventing bacterial vaginosis (BV) recurrence in women diagnosed with BV; the safety of LACTIN-V will also be studied.  For more information, please visit the national website

Women’s Interagency HIV Study (WIHS)

Established in August 1993, the WIHS studies the impact of HIV infection on women in the United States. The Chicago consortium is one of nearly a dozen WIHS sites across the US. The nearly 300 active participants in the Chicago WIHS show extraordinary commitment, participating in two comprehensive research visits annually, along with additional sub-study visits when available. The data gathered through these visits contributes to our knowledge about the physical, emotional and social health of HIV positive women. The Chicago WIHS program includes women from, and collaboration with, Northwestern, UIC, and Rush University Medical Center. For additional information, please visit the national WIHS website at

Adolescent and Young Adult Research (AYAR)

The Adolescent and Young Adult Research (AYAR) section conducts research that may improve the lives of youth at risk of becoming infected with HIV (and other infections) and youth who are already infected through better treatment methods. Since 2009, the adolescent research team has been a national leader in prevention research including Pre-Exposure Prophylaxis (PrEP). Research also includes work with medication adherence and behavioral issues. For additional information, please email

Pre-Exposure Prophylaxis (PrEP) Research

The CORE Center leadership in PrEP research continues today through various paths. In addition to protocols executed through AYAR, the CORE Center offers investigator-initiated PrEP research and studies available through collaboration with colleagues—these studies are possible through pharmaceutical and federal funding mechanisms. CORE offers PrEP studies for individuals at high risk including, young men who have sex with men, transgender women, and cis-gender women.

HPTN 083 is a NIH funded trial to evaluate the safety and efficacy of injectable Cabotegravir LA—this allows for a bimonthly injection vs a daily pill for PrEP; Gilead 2055 is funded by Gilead Sciences to evaluate their drug F/TAF for use as PrEP—F/TAF was first FDA approved as HIV treatment;

ITECH includes the LYNX protocol to study a novel phone app to support linkage to HIV/STI testing and PrEP;

A TEAM is a NIH funded investigator-initiated study using a new biomedical technology to monitor adherence to PrEP;

Women’s PrEP Study will evaluate women’s knowledge, acceptance and adherence to PrEP—this study is a collaboration with Rush University Medical Center and Rutgers University (NJ).

Adult Clinical Trials

The adult clinical trials program includes industry-sponsored and investigator-initiated research. Studies offered are in the areas of HIV treatment, hepatitis C treatment and adherence, STI treatment, cancer treatment, and vaccine studies. Please contact the coordinator at (312) 572-4543 to learn what trials are currently open for enrollment.